For Immediate Release: October 21, 2014 Medpace Contact: Mary Kuramoto, +1 513-579-9911 X2523 [email protected] Medpace Expands Therapeutic Leadership in Global Infectious Disease Drug Development Dr. Anibal Ruben Calmaggi Joins Medpace as Senior Medical Director for Infectious Disease CINCINNATI, OH — (October 21, 2014) – Anibal Ruben Calmaggi, MD has joined Medpace as Senior Medical Director for infectious disease clinical research. Medpace, a global drug and medical device Clinical Research Organization (CRO), is known for its strong therapeutic and regulatory expertise across key therapeutic areas including infectious disease. Dr. Calmaggi is based in Argentina and will extend Medpace’s ability to support global trials with hands-on medical leadership, collaboration and site feasibility in Latin America. Dr. Calmaggi brings a strong background in clinical development with over 10 years of director-level clinical operations and medical affairs experience with board certification in Infectious Disease. His background includes supporting drug development across the full range of infectious diseases including Hepatitis C and HIV, as well as nuclear cardiology, rheumatoid arthritis, and cystic fibrosis. About Anibal Ruben Calmaggi, MD Dr. Anibal Ruben Calmaggi received his MD degree Suma Cum Laude from the Universidad Nacional de La Plata La Plata, Buenos Aires, Argentina and board certification in Infectious Diseases specialty from the Colegio Médico de la Provincia de Buenos Aires Buenos Aires, Argentina. Most recently, Dr. Calmaggi served as Senior Director, Clinical Development at Cerexa, Inc, a wholly-owned subsidiary of Forest Laboratories, Inc. Prior to this, Dr. Calmaggi was Sr. Medical Director, Medical and Scientific Affairs at a global CRO where he served as therapeutic leader in infectious diseases for the respiratory and infectious disease therapeutic business unit. His combined experience from the Sponsor and CRO perspectives will provide leadership and valuable insights into global infectious disease drug development programs. About Medpace Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, and gastroenterology. With extensive medical expertise, and a renowned regulatory affairs department, Medpace employs over 2000 employees and has clinical trial experience in over 45 countries and 6 regions in the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management. Learn more about Medpace at www.medpace.com.